SCHEMBL3917005

SCHEMBL3917005

CC(Cc1cccc(CC(=O)N2CCN(c3ccccn3)CC2)c1)NCC(O[Si](C)(C)C(C)(C)C)c1cc(O)cc(O)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 0.46
ALDH1A1 P00352 6/20 0.46
HSD17B10 Q99714 5/20 0.46
HPGD P15428 4/20 0.46
NPSR1 Q6W5P4 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
POLB P06746 1/20 0.41
KMT2A Q03164 3/20 0.40
MEN1 O00255 1/20 0.40
LMNA P02545 2/20 0.40
CASP1 P29466 1/20 0.40
ME2 P23368 1/20 0.39
ME1 P48163 1/20 0.39
ME3 Q16798 1/20 0.39
MAPT P10636 2/20 0.38
CYP2C9 P11712 2/20 0.38
CYP1A2 P05177 1/20 0.38
MAPK1 P28482 1/20 0.38
CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13840684 1.00 KDM4E (0.46) KDM4EALDH1A1HSD17B10HPGDNPSR1
SCHEMBL3924705 0.85 ADRB2 (0.52) KDM4EALDH1A1HSD17B10HPGDNPSR1
SCHEMBL13840821 0.85 ADRB2 (0.52) KDM4EALDH1A1HSD17B10HPGDNPSR1
SCHEMBL3917533 0.80 ADRB2 (0.46) HSD17B10NPSR1MAPK1CYP3A4
SCHEMBL13840631 0.80 ADRB2 (0.46) HSD17B10NPSR1MAPK1CYP3A4
SCHEMBL13840634 0.80 ADRB2 (0.45) HSD17B10NPSR1MAPK1CYP3A4
SCHEMBL13840675 0.76 GAA (0.42) ALDH1A1KMT2AMEN1MAPK1
SCHEMBL3986903 0.76 GAA (0.42) ALDH1A1KMT2AMEN1MAPK1
SCHEMBL3915463 0.76 KDM4E (0.49) KDM4EALDH1A1HSD17B10HPGDNPSR1
SCHEMBL3913856 0.75 ADRB2 (0.47) HSD17B10NPSR1MAPK1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1730141-B1 COMPOUNDS FOR THE TREATMENT OF DISEASES PFIZER LTD (GB) 2009-05-27 EP disclosed
US-7538141-B2 Compounds for the treatment of diseases PFIZER INC. 2009-05-26 US disclosed
EP-1730141-A1 COMPOUNDS FOR THE TREATMENT OF DISEASES Pfizer Limited (GB) 2006-12-13 EP disclosed
US-20050222128-A1 Compounds for the treatment of diseases PFIZER INC 2005-10-06 US disclosed
WO-2005092887-A1 COMPOUNDS FOR THE TREATMENT OF DISEASES PFIZER LIMITED (GB) 2005-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222128-A1 Compounds for the treatment of diseases LTC4S, LTB4R2, CYP11B2 KDM4E 4224/4885ALDH1A1 128/4885HSD17B10 470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.